69 research outputs found
Diagnosis of vertebral fractures in children: is a simplified algorithm-based qualitative technique reliable?
Background Identification of osteoporotic vertebral fractures
allows treatment opportunity reducing future risk. There is no
agreed standardised method for diagnosing paediatric vertebral
fractures.
Objective To evaluate the precision of a modified adult
algorithm-based qualitative (ABQ) technique, applicable to
children with primary or secondary osteoporosis.
Materials and methods Three radiologists independently
assessed lateral spine radiographs of 50 children with
suspected reduction in bone mineral density using a modified
ABQ scoring system and following simplification to include
only clinically relevant parameters, a simplified ABQ score. A
final consensus of all observers using simplified ABQ was
performed as a reference standard for fracture characterisation.
Kappa was calculated for interobserver agreement of the
components of both scoring systems and intraobserver agreement
of simplified ABQ based on a second read of 29 randomly
selected images.
Results Interobserver Kappa for modified ABQ scoring for
fracture detection, severity and shape ranged from 0.34 to
0.49 Kappa for abnormal endplate and position assessment
was 0.27 to 0.38. Inter- and intraobserver Kappa for simplified
ABQ scoring for fracture detection and grade ranged from
0.37 to 0.46 and 0.45 to 0.56, respectively. Inter- and
intraobserver Kappa for affected endplate ranged from 0.31
to 0.41 and 0.45 to 0.51, respectively. Subjectively, observersâ
felt simplified ABQ was easier and less time-consuming.
Conclusion Observer reliability of modified and simplified
ABQ was similar, with slight to moderate agreement for fracture
detection and grade/severity. Due to subjective preference
for simplified ABQ, we suggest its use as a semi-objective
measure of diagnosing paediatric vertebral fracture
Importance of dynamic contrast enhanced magnetic resonance imaging for targeting biopsy and salvage treatments after prostate cancer recurrence
Purpose: Evaluate T2 weighted MRI (T2W), diffusion weighted imaging (DWI), and dynamic contrast enhanced MRI (DCE-MRI) for determining areas of prostate cancer recurrence to target biopsy or salvage treatment in patients previously treated with I-125 seed brachytherapy.
Material and methods: MRI data from 15 patients, whose primary treatment was I-125 seed brachytherapy and who were subsequently treated with partial gland salvage high-dose-rate brachytherapy were retrospectively analyzed. Two radiologists independently reviewed imaging on two occasions blinded to clinical and biopsy information. At first review, the T2W and DWI sequences were assessed for likely presence of tumor and at second review, the additional DCE-MRI sequence was assessed. Results were recorded and compared on a prostate diagram divided into 12 sectors (quadrants at each of base, mid-gland, and apex) plus seminal vesicles (SV).
Results: Number of patients for whom recurrence was visible was 7/15 for T2W, 6.5/15 for DWI, and 15/15 for DCE-MRI (average of results for the two radiologists). Approximately, half of the sectors identified as showing recurrence were at the anterior base of the prostate.
Conclusions: In prostate cancer patients previously treated with I-125 permanent seed implants, DCE-MRI is superior to T2W and DWI in defining areas of recurrence, and should be used to target biopsy and for treatment planning of focal salvage therapies
Diagnostic accuracy of DXA compared to conventional spine radiographs for the detection of vertebral fractures in children
Objectives
In children, radiography is performed to diagnose vertebral fractures and dual energy x-ray absorptiometry (DXA) to
assess bone density. In adults, DXA assesses both. We aimed to establish whether
DXA can replace spine radiographs in assessment of paediatric vertebral fractures.
Methods
Prospectively, lateral spine radiographs and lateral spine DXA of 250 children
performed on the same day were independently scored by three radiologists using
the simplified algorithm based qualitative technique and blinded to results of the
other modality. Consensus radiograph read and second read of 100 random images
were performed. Diagnostic accuracy, inter/intraobserver and intermodality
agreements, patient/carer experience and radiation dose were assessed.
Results
Average sensitivity and specificity (95% confidence interval) in diagnosing one or
more vertebral fractures requiring treatment was 70% (58%-82%) and 97% (94%-
100%) respectively for DXA and 74% (55%-93%) and 96% (95%-98%) for
radiographs. Fleissâ kappa for interobserver and average kappa for intraobserver
reliability were 0.371 and 0.631 respectively for DXA and 0.418 and 0.621 for
radiographs. Average effective dose was 41.9”Sv for DXA and 232.7”Sv for
radiographs. Image quality was similar.
Conclusion
Given comparable image quality and non-inferior diagnostic accuracy, lateral spine
DXA should replace conventional radiographs for assessment of vertebral fractures
in children
Efficacy and toxicity outcomes for patients treated with focal salvage high dose rate brachytherapy for locally recurrent prostate cancer
Introduction
Isolated local recurrence of prostate cancer following primary radiotherapy or brachytherapy may be treated with focal salvage high dose rate brachytherapy, although there remains an absence of high quality evidence to support this approach.
Methods
Men with prostate cancer treated consecutively between 2015 and 2018 using 19 Gy in a single fraction high dose rate brachytherapy (HDR) for locally recurrent prostate cancer were identified from an institutional database. Univariable analysis was performed to evaluate the relationship between patient, disease and treatment factors with biochemical progression free survival (bPFS).
Results
43 patients were eligible for evaluation. Median follow up duration was 26 months (range 1â60). Median bPFS was 35 months (95% confidence interval 25.6â44.4). Kaplan-Meier estimates for bPFS at 1, 2 and 3 years post salvage were 95.2%, 70.6% and 41.8% respectively. On univariable Cox regression analysis, only nadir PSA was significantly associated with bPFS although the majority of patients were also treated with androgen deprivation therapy. Only one late grade 3 genitourinary toxicity was observed.
Conclusion
Focal salvage HDR brachytherapy may provide good biochemical control with a low risk of severe toxicity. Further evaluation within clinical trials are needed to establish its role in the management of locally recurrent prostate cancer
Response to âUnexpected lower biochemical control of high-dose-rate brachytherapy boost than low-dose-rate brachytherapy boost for clinically localized prostate cancerâ
A comparison of outcomes for patients with intermediate and high risk prostate cancer treated with low dose rate and high dose rate brachytherapy in combination with external beam radiotherapy
Introduction
There is evidence to support use of external beam radiotherapy (EBRT) in combination with both low dose rate brachytherapy (LDRâEBRT) and high dose rate brachytherapy (HDRâEBRT) to treat intermediate and high risk prostate cancer.
Methods
Men with intermediate and high risk prostate cancer treated using LDRâEBRT (treated between 1996 and 2007) and HDRâEBRT (treated between 2007 and 2012) were identified from an institutional database. Multivariable analysis was performed to evaluate the relationship between patient, disease and treatment factors with biochemical progression free survival (bPFS).
Results
116 men were treated with LDR-EBRT and 171 were treated with HDRâEBRT. At 5âŻyears, bPFS was estimated to be 90.5% for the LDRâEBRT cohort and 77.6% for the HDRâEBRT cohort. On multivariable analysis, patients treated with HDRâEBRT were more than twice as likely to experience biochemical progression compared with LDRâEBRT (HR 2.33, 95% CI 1.12â4.07). Patients with Gleason â„8 disease were more than five times more likely to experience biochemical progression compared with Gleason 6 disease (HR 5.47, 95% CI 1.26â23.64). Cumulative incidence of â„grade 3 genitourinary and gastrointestinal toxicities for the LDRâEBRT and HDRâEBRT cohorts were 8% versus 4% and 5% versus 1% respectively, although these differences did not reach statistical significance.
Conclusion
LDRâEBRT may provide more effective PSA control at 5âŻyears compared with HDRâEBRT. Direct comparison of these treatments through randomised trials are recommended to investigate this hypothesis further
Recommended from our members
Reâevaluation of gellan gum (E 418) as food additive
The Panel on Food Additives and Nutrient Sources added to Food (ANS) provides a scientific opinion reâevaluating the safety of gellan gum (E 418) as a food additive. Following the conceptual framework for the risk assessment of certain food additives reâevaluated under Commission Regulation (EU) No 257/2010, the Panel considered that adequate exposure and toxicity data were available. Based on the reported use levels, a refined exposure of up to 72.4 mg/kg body weight (bw) per day in toddlers at the 95th percentile was estimated. Gellan gum is unlikely to be absorbed intact and would not be fermented by human intestinal microbiota. There is no concern with respect to carcinogenicity and genotoxicity. No adverse effects were reported in chronic studies at the highest doses tested in mice and rats (3,627 and 1,460 mg gellan gum/kg bw per day, respectively). Repeated oral intake up to 200 mg/kg bw per day for 3 weeks had no adverse effects in humans. The Panel concluded that there is no need for a numerical acceptable daily intake (ADI) for gellan gum (E 418), and that there is no safety concern at the refined exposure assessment for the reported uses and use levels of gellan gum (E 418) as a food additive. The Panel recommended to better define the specifications of gellan gum including the absence of viable cells of the microbial source and the presence of polyhydroxybutyrate (PHB), protein and residual bacterial enzymatic activities
Pectin extracted from thermally treated olive oil by-products: Characterization, physico-chemical properties, in vitro bile acid and glucose binding
ADEPT - Abnormal Doppler Enteral Prescription Trial
<p>Abstract</p> <p>Background</p> <p>Pregnancies complicated by abnormal umbilical artery Doppler blood flow patterns often result in the baby being born both preterm and growth-restricted. These babies are at high risk of milk intolerance and necrotising enterocolitis, as well as post-natal growth failure, and there is no clinical consensus about how best to feed them. Policies of both early milk feeding and late milk feeding are widely used. This randomised controlled trial aims to determine whether a policy of early initiation of milk feeds is beneficial compared with late initiation. Optimising neonatal feeding for this group of babies may have long-term health implications and if either of these policies is shown to be beneficial it can be immediately adopted into clinical practice.</p> <p>Methods and Design</p> <p>Babies with gestational age below 35 weeks, and with birth weight below 10th centile for gestational age, will be randomly allocated to an "early" or "late" enteral feeding regimen, commencing milk feeds on day 2 and day 6 after birth, respectively. Feeds will be gradually increased over 9-13 days (depending on gestational age) using a schedule derived from those used in hospitals in the Eastern and South Western Regions of England, based on surveys of feeding practice. Primary outcome measures are time to establish full enteral feeding and necrotising enterocolitis; secondary outcomes include sepsis and growth. The target sample size is 400 babies. This sample size is large enough to detect a clinically meaningful difference of 3 days in time to establish full enteral feeds between the two feeding policies, with 90% power and a 5% 2-sided significance level. Initial recruitment period was 24 months, subsequently extended to 38 months.</p> <p>Discussion</p> <p>There is limited evidence from randomised controlled trials on which to base decisions regarding feeding policy in high risk preterm infants. This multicentre trial will help to guide clinical practice and may also provide pointers for future research.</p> <p>Trial registration</p> <p>Current Controlled Trials ISRCTN: 87351483</p
Recommended from our members
Reâevaluation of celluloses E 460(i), E 460(ii), E 461, E 462, E 463, E 464, E 465, E 466, E 468 and E 469 as food additives
Following a request from the European Commission, the EFSA Panel on Food Additives and Nutrient sources added to Food (ANS) was asked to deliver a scientific opinion on the re-evaluation of microcrystalline cellulose (E 460(i)), powdered cellulose (E 460(ii)), methyl cellulose (E 461), ethyl cellulose (E 462), hydroxypropyl cellulose (E 463), hydroxypropyl methyl cellulose (E 464), ethyl methyl cellulose (E 465), sodium carboxy methyl cellulose (E 466) and enzymatically hydrolysed carboxy methyl cellulose (E 469) as food additives. The Joint FAO/WHO Expert Committee on Food Additives (JECFA) and the Scientific Committee on Food (SCF) established an acceptable daily intake (ADI) ânot specifiedâ for unmodified and modified celluloses. Celluloses are not absorbed and are excreted intact in the faeces; in addition, microcrystalline cellulose, powdered and modified celluloses could be fermented by the intestinal flora in animals and humans. Specific toxicity data were not always available for all the celluloses evaluated in the present opinion and for all endpoints. Given their structural, physicochemical and biological similarities, the Panel considered it possible to read-across between all the celluloses. The acute toxicity of celluloses was low and there was no genotoxic concern. Short-term and subchronic dietary toxicity studies performed with E 460(i), E 461, E 462, E 463, E 464, E 466 and E 469 at levels up to 10% did not indicate specific treatment related adverse effects. In chronic toxicity studies performed with E 460(i), E 461, E 463, E 464, E 465 and E 466, the no observed adverse effect level (NOAEL) values reported ranged up to 9,000 mg/kg body weight (bw) per day. No carcinogenic properties were detected for microcrystalline cellulose and modified celluloses. Adverse effects on reproductive performance or developmental effects were not observed with celluloses at doses greater than 1,000 mg/kg bw by gavage (often the highest dose tested). The combined exposure to celluloses (E 460â466, E 468 and E 469) at 95th percentile of the refined (brand-loyal) exposure assessment for the general population was up to 506 mg/kg bw per day. The Panel concluded that there was no need for a numerical ADI and that there would be no safety concern at the reported uses and use levels for the unmodified and modified celluloses (E 460(i); E 460(ii); E 461â466; E 468 and E 469). The Panel considered an indicative total exposure of around 660â900 mg/kg bw per day for microcrystalline, powdered and modified celluloses
- âŠ